Q-omics provides the consensus-scored CORO7-PAM16 profile across patient tissues and cancer cell-line models. CORO7-PAM16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CORO7-PAM16 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, CORO7-PAM16 RNA expression shows 10,609 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRP as cancer lineages where CORO7-PAM16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORO7-PAM16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORO7-PAM16 survival associations across molecular data types. CORO7-PAM16 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORO7-PAM16 RNA expression–survival associations across cancer types. High CORO7-PAM16 expression shows unfavorable associations in ACC, LIHC and KIRC, but favorable associations in SCLC, LUAD and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for CORO7-PAM16 RNA expression.
This table summarizes CORO7-PAM16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CORO7-PAM16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORO7-PAM16 shows lower tumor expression in BLCA, LUSC and UCEC and higher tumor expression in KIRP, KIRC and LIHC. The KIRP box plot shows higher CORO7-PAM16 RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p < 0.001).
This table shows molecular features associated with CORO7-PAM16 in patient tissues and cancer cell lines. In patient samples, CORO7-PAM16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CORO7-PAM16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
